Antimicrobials
DAPTOmycin

DAPTOmycin

Restricted

Low
N/A

Spectrum of Activity

General Information

Targeted therapy of resistant gram positive infections with MRSA (particularly when MIC>=2) and VRE including endovascular infection

Creatine kinase weekly, renal function

  • Myopathy including rhabdomyolysis
  • GI side effects common
  • Rash
  • Phlebitis
  • Increased INR

Statins and fibrates: Monitor creatine kinase or hold while on daptomycin therapy (increased myopathy)

Recommend Infectious Disease Consult

Inactivated by pulmonary surfactant and therefore insufficient for pulmonary infection

Antimicrobial class: Cyclic lipopeptide, depolarizes bacterial cell membrane

Average serum half life:

  • Neonates and Infants <3 months: 6.2 hours
  • Children: 5 to 7 hours

Route of Elimination: 78% of the dose excreted in urine as unchanged drug; feces (6%)